Insight Molecular Diagnostics Inc. (IMDX) Return on equity 2020–2023
Insight Molecular Diagnostics Inc. (IMDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-135.7%FY2023 · since FY2020: -89.4% → -135.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -135.7% | +76.9 pp |
| FY2022 | -212.6% | -114.3 pp |
| FY2021 | -98.3% | -8.9 pp |
| FY2020 | -89.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More IMDX financial trends
IMDX RevenueIMDX Net incomeIMDX Net marginIMDX Gross profitIMDX Gross marginIMDX Operating incomeIMDX Operating marginIMDX Operating cash flowIMDX Free cash flowIMDX Capital expendituresIMDX Stock buybacksIMDX Dividends paidIMDX Total assetsIMDX Total liabilitiesIMDX Shareholders’ equityIMDX overview →